VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting

TEL AVIV, Israel, May 11, 2017 (GLOBE NEWSWIRE) — VBL Therapeutics (VBLT) today announced new preclinical data indicating that treatment with ofranergene obadenovec (VB-111) augments the anti-tumor activity of a PD-L1 blocker in lung cancer and melanoma models. The data will be presented tomorrow, May 12, in a poster session at the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place in Washington, DC.